anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Parenting children with developmental disabilities or Autism Spectrum Disorder (ASD) can be challenging. Often, these children process information in an atypical manner and they may struggle to learn through social engagement. At times, regular parenting techniques do not work with these children, which may leave parents feeling distressed and confused. In their ground breaking interpretation of the International Classification of Functioning, Health and Disability (ICF), The 'F-words' in childhood disability, (2011) Dr. P. Rosenbaum and Dr. J. Gorter state that, "Family represents the essential environment of all children." They point to research that confirms that parental physical and mental health is challenged in families who have a child with a disability. Specifically, behavioural issues of these children significantly contribute to parental stress scores, impact attachment, the relationship with a spouse, parental depression and in particular, a sense of competence. By providing parents the opportunity to understand their child's unique learning style, and the opportunity to learn how to mindfully engage their child, it is the investigators' goal to restore parental competence and the natural parent/child relationship.

The objectives of this new learning series program are to help parents understand their child's unique learning style and to give parents the practical tools to become their child's best teacher and guide. Becoming a mindful parent requires a solid understanding of the child's underlying social learning challenges, and it requires parents to be both self-reflective and analytical. Behaviour change takes time and repeated experience. Parents also need the opportunity to practice in a safe and supportive environment. This learning series will consist of ten in-person sessions, over a period of 12-14 weeks.
Methods are provided for the generation of nanostructures suitable for use in magnetic resonance imaging where the nanostructures have at least one dimension of about 2 nm or less. In particular, the methods comprise the selective use of incubation temperatures that result in the controlled removal of ligands from metallic cores to which they are attached, allowing the metallic cores or the precursor moieties to unite to form nanostructures of defined and predictable shapes, but having at least one dimension significantly less that at least one other dimension. Accordingly, the nanostructures of the disclosure may be ultrathin sheets, rods, whiskers and the like, or even structures that are thin and porous resembling rice grains. The temperatures useful in the methods of the disclosure are less than 300° C. and allow for progressive elevation of the incubation temperature. The methods are especially advantageous for synthesizing nanoparticles that may be administered to an animal or human subject for imaging with magnetic resonance. Accordingly, the nanostructures of the disclosure comprise a metallic core, most typically, but not necessarily limited to, a ferrite moiety that can be a ferrous or ferric ion alone or in combination with other metallic elements. However, the methods of the disclosure are also suitable for generating nanostructures with non-ferrous cores such as magnesium or manganese cores.
Investigating infectious agents in porcine abortion material and stillborn piglets poses challenges for practitioners and diagnostic laboratories. In this study, pooled samples of individual reference organs (thymus and heart) from a total of 1000 aborted fetuses and stillborn piglets were investigated using quantitative PCR protocols for porcine reproductive and respiratory syndrome virus 1 (PRRSV-1) and porcine circovirus type 2 (PCV2). Simultaneously, a pluck-pool containing equivalent portions of fetal thymus, heart, and lung tissue was collected, frozen at - 20 °C, and re-analyzed when a certain amount of either PRRSV-1 RNA or PCV2 DNA was detected in individual reference organs. Thirteen pluck-pools were assessed for PRRSV-1, all being PCR-positive. For PCV2, 11 of 15 pluck-pools investigated were PCR-positive. In all pluck-pools testing negative, viral loads in individual pools were low. This study indicates that pluck-pools can be valuable diagnostic material and the consolidation of multiple organs through a single RNA/DNA extraction optimizes the utilization of available laboratory resources. Additional research is required to assess the feasibility of follow-up investigations and to accurately define criteria for interpretation of viral loads in a clinical context.
The present disclosure describes embodiments of a computer-implemented method for controlling an anesthetic fluid flow executed on a computer unit and a system, computer-readable media, and computer program associated with the execution of said method. In the method, an input data packet including demographic data and physiological data of a user, and target concentration data is received. Further, the method obtains a first value of a configuration data with a pharmacokinetic processing method from the input data packet. Also, the first configuration data in the method is entered into an anesthetic fluid infusion pump, and a status data is received from an instrumentation system. The status data includes records of at least one variable associated with the anesthetic status and brain condition of the patient. Additionally, the method takes into account a threshold range that is obtained from a pharmacodynamic processing method. Furthermore, the method has a step of obtaining a second setting data value by performing a control process that selectively takes as input the first setting data value, the state data, and the threshold, and performs a PID control method and/or a fuzzy control method to get the second value of the configuration data. Then, the configuration data with the second value is sent to the anesthetic fluid infusion pump to modify its flow conditions. The method iterates the stages in which the setting data value is recalculated based on the state of the user under anesthesia.
The objective of the project is to study clinical and prognostic value of new echocardiographic technique, so called positive preejection velocity (+VIC), in patients with chronic ischemic left ventricular (LV) dysfunction indicated for revascularization. Pilot studies has shown high accuracy of pulsed Tissue Doppler imaging (TDI)-derived resting pattern of +VIC to detect viable myocardium in patients with both acute myocardial infarction and chronically dysfunctional myocardium. The aim of the project is to test accuracy of +VIC to predict LV remodeling and long-term prognosis after revascularization in patients with chronically dysfunctional myocardium. Study population will consist of two groups of patients with stable ischemic LV dysfunction: group A- patients indicated for revascularization (n=200), group B- matched control group treated conservatively (case-control design) (n=100). All patients will be followed for 3 years. Endpoints include: 1) LV remodeling at 6 and 24 months and 2) MACE at 6, 12 and 36 months follow-up. Our hypothesis is that TDI-derived analysis of +VIC allows to select optimal responders to revascularization; it means individuals with the greatest benefit in terms of LV remodeling and long-term prognosis.
The invention provides novel application of Java brucea fruit oil emulsion injection to the anticancer aspect, in particular to novel application to the anti-leukemia aspect. The invention respectively uses humanized leukemia U937, NB4 and HL-60 cell strains and humanized prostatic carcinoma Du145 cell strains as target cells, and studies the inhabiting effect of the Java brucea fruit oil emulsion injection on the blood system tumor and the urogenital system tumor. The invention discovers that the Java brucea fruit oil emulsion injection has the inhabiting effect on the humanized leukemia HL-60, NB4 and U937cell strains and the humanized prostatic carcinoma Du145 cell strains for the first time, and the inhabiting effect is improved along with the gradual increase of the dosage. In addition, the Java brucea fruit oil emulsion injection can also induce the apoptosis of the humanized leukemia cells, and also has the apoptosis induction effect on the primary dissociated leukemia cells. In addition, the bruceolic oil emulsion injection liquid has low cell toxic effect on peripheral blood lymphocytes of normal persons. The results show that the Java brucea fruit oil emulsion injection has certain potential in the aspect of leukemia treatment, and can provide high-efficiency and low-toxicity medicine for the leukemia treatment.
For the IPSS Low- or intermediate-1-risk del (5q) (MDS), Lenalidomide treatment must not be started if the ANC \< 0.5 x 109/L and/or platelet counts \< 25 x 109/L. The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
PURPOSE: To produce a dispersion of microcapsules excellent in property of slowly releasing a housed volatile matter and capable of releasing the volatile matter over a long period of time. CONSTITUTION: An oily liq. contg. a volatile matter, a multifunctional isocyanate, a water-insoluble polyol and an organotin compd. is added to an aq. liq. contg. a polyamine having at least two amino groups and an emulsifier, and the oily liq. is emulsified, dispersed and brought into a resinification reaction to obtain the objective dispersion of microcapsules each consisting of a gelatinous polyurethane resin core 1 contg. the volatile matter and a polyurea resin shell 2 formed on the periphery of the core 1.
NEW MATERIAL:The compound of formula I (R1 is CH3 or CH2OH; R2 is H or Ac; R3 is H or alkali metal such as Na, K, etc.) and its alkali metal salt. EXAMPLE:9-Desoxo-9-hydroxy-pheophorbide sodium salt. USE:A carcinostatic agent. It has excellent affinity to cancer tissue, reactivity with light, and destructive activity of cancer cell. It can be synthesized and separated from a stably available inexpensive raw material easily in a short time. PREPARATION:The compound of formula I can be produced by reducing the pheophorbide of formula II with a reducing agent (e.g. NaBH4, Na2S2O3, etc.) in a solvent such as methanol, pyridine, etc.
OBJECTIVES: This study compared levels of discomfort among three positions for ultrasound-guided carpal tunnel injections (USCTI) to potentially facilitate and improve the procedure's tolerability in treating carpal tunnel syndrome (CTS).
METHODS: Ambulatory Veterans referred for electromyography (EMG) evaluation of CTS were eligible for the study; a total of 30 participants were evaluated. Participants were asked to hold three different positions: 1) Hypersupination, 2) Airplane, and 3) total supported abduction (TSA). Participants rated their pain level, ease of performing/holding each position, exacerbation of underlying symptoms, and position preference. Results were analyzed with two-way repeated measures ANOVA.
RESULTS: Hypersupination was determined to be the least preferred and most painful position to hold, demonstrating a statistically significant increase in the Numeric Rating Scale score for pain during the procedure compared with Airplane and TSA, which were not significantly different from one another. Pre-procedure neck, shoulder, elbow, and wrist pain were not significantly associated with intra-procedure pain.
CONCLUSIONS: When performing USCTI, patient comfort can be optimized by avoiding Hypersupination. Utilizing the Airplane or TSA positions may provide similar access for ulnar approach injections while inducing lower levels of discomfort. Clinical space, resources, patient mobility, and laterality of procedures may further guide one's selection among the positions.
Patients with chronic non-healing wounds often have major co-morbidities such as diabetes and cardiovascular diseases \[1\]. Obstructive Sleep Apnea (OSA) is present in up to 24% of middle-aged adults \[2\], and is far more prevalent in patients with existing cardiovascular disease \[3\]. Patients with OSA are at increased risk of developing diabetes l \[4\]. OSA is an established cause of hypertension\[5\], and has an estimated prevalence of 40% in all patients with hypertension \[6-8\]. Similarly a strong association exists between OSA, coronary artery disease \[6, 7\] and stroke \[8\]. OSA may be present in over 50% of patients with heart failure \[9\]. Patients with chronic non-healing wounds stand to benefit from identification and treatment of severe co-morbidities such as OSA. Such identification and treatment of OSA will impact the survival of these patients \[10, 11\], and may also contribute to improved morbidity via impacting wound healing.

Several unexplored links exist between OSA and wound healing. OSA is a disorder of intermittent hypoxia and is associated with increased oxidative stress \[12\]. Humans with OSA and animal models of intermittent hypoxia developed impaired vascular function and nitric oxide deficiency. Patients with OSA have impaired endothelial function even in the absence of clinically apparent cardiovascular disease \[13-15\]. Increased sympathetic activity and episodic pressor response are well documented in OSA. Patients with OSA have increased vascular tone and baseline vasoconstriction \[16\]. Impaired vascular reactivity to hypoxia was also demonstrated in animal models exposed to 2 weeks of intermittent hypoxia\[17\]. Therefore, in patients with chronic non-healing wounds, OSA is likely to further complicate the healing process.

OSA as a disorder of oxidative stress and vascular impairment is most likely an important co-morbidity in patients with non-healing wounds. Other potential mechanisms of interaction are the inflammatory response associated with OSA
Epistaxis and Nasal Ulceration: In placebo (vehicle nasal spray)-controlled clinical trials of 2 weeks to 12 months duration, epistaxis and nasal ulcerations were reported [see Adverse Reactions (6)].

Nasal Septal Perforation:

Two placebo (vehicle nasal spray)-controlled long term (12 months) safety trials were conducted. In the first safety trial, patients were treated with an investigational formulation of PATANASE Nasal Spray containing povidone (not the commercially marketed formulation) or a vehicle nasal spray containing povidone. Nasal septal perforations were reported in one patient treated with the investigational formulation of PATANASE Nasal Spray and 2 patients treated with the vehicle nasal spray. In the second safety trial with PATANASE Nasal Spray, which does not contain povidone, there were no reports of nasal septal perforation [see Adverse Reactions (6)].

Before starting PATANASE Nasal Spray, conduct a nasal examination to ensure that patients are free of nasal disease other than allergic rhinitis. Perform nasal examinations periodically for signs of adverse effects on the nasal mucosa and consider stopping PATANASE Nasal Spray if patients develop nasal ulcerations.
After a 2-week placebo run-in, participants received extended release (ER) niacin/laropiprant (N/LRPT) 1 g/20 mg combination tablet (MK-0524B) once daily for 4 weeks, then ERN/LRPT/Simvastatin (SIM) 2 g/40 mg combination tablet once daily for 8 weeks. Participants then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks.
FIELD: biotechnology, food and medicinal industry. SUBSTANCE: invention proposes the consortium of bifidobacteria and lactobacilli Bifidobacterium bifidum 1, B. bifidum 791, B. breve 79-88, B. infantis 79-43, B. longum B379M, Lactobacillus plantarum 8-PA-3, L. fermentum 90-TC-4, Lactobacillus acidophilus K3sh24 from GKNM MNIIEM named after G. N. Gabritchevsky, N 160, used for preparing bacterial preparations, ferments for fermented-milk foodstuffs, fermented and nonfermented foodstuffs, biologically active supplements. The consortium is designated for correction of microflora in children of age from 3 to 12 years. The consortium is designated for correction of microflora in intestine, mucosa, opened cavities and cutaneous integuments in children of age from 3 to 12 years, it shows immunocorrecting effect and provides the enhanced protective, immunotropic, metabolic and digestive functions due to synergetic effect of bifidobacterium and lactobacillus components of consortium stimulating the growth of normal microflora. EFFECT: enhanced effectiveness of consortium, expanded assortment of curative- prophylactic agents. 3 tbl, 5 ex
This study is a randomized, double-blind, single-center, controlled phase III clinical trial in children aged 36-71 months, and bridging trial between agegroup of 6-35 and 36-71 months. The purpose of this study is to evaluate the immunogenicity and safety of the experimental EV71 vaccine in children aged 36-71 months. The primary objective of this study is to evaluate the non-inferiority of experimental EV71 vaccine compared to the control EV71 vaccine in children aged 36-71 months, and the non-inferiority of EV71 vaccine used in children aged 36-71 months compared to 6-35 months. The secondary objective is to evaluate the safety of the experimental vaccine used in children aged 36-71 months. The experimental vaccine is manufactured by Sinovac Biotech Co., Ltd, and the control vaccine is manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences. 600 children aged 36-71 months will be randomly assigned in to receive the experimental vaccine or control vaccine, and 300 children aged 6-35 months will receive the experimental vaccine.
Brachial plexus injuries can cause severe disabilities and often affect young adults and newborn children. When initial conservative treatment or nerve surgery fails, muscle/tendon transfers are the only current treatment options available to regain a functional arm. During this extensive surgery a healthy donor muscle is transposed to exert a different function. After long-term denervation the muscle is irreversibly changed. Muscle atrophy, fattening, fibrosis, decrease in capillary to muscle fiber ratio and decline in the number of satellite cells, which are responsible for post-natal muscle repair, is seen. For neuromuscular diseases, cell therapy aiming at rescuing muscle damage by delivery of cells that can differentiate into skeletal muscle, might be a promising approach. Safety questions remain whether stem cell injection results in non-muscle tissue formation like inflammatory cells or connective tissue formation in the transplanted muscles. Furthermore, it remains to be determined whether these stem cells undergo functional integration and enhance muscle function. The objective of this pilot study is to assess functional and morphological improvement of the m. biceps brachii after autologous bone marrow-derived mononuclear cell injection.
Systems and methods are provided for automatically scheduling patient visits based on information in electronic medical records (EMRs). In one exemplary embodiment, a computer-implemented method for scheduling patient visits based on information in EMRs may be provided and performed by one or more computers associated with a service provider. An EMR for a patient can be evaluated to determine if it contains information indicating a need to schedule a future vising for the patient. Multiple scheduling parameters can be identified in the EMR. A schedule for a healthcare provider can be received, for example by the service provider computer. The schedule of the healthcare provider can be evaluated based on one or more of the identified scheduling parameters. In addition, a suggested appointment time for the future visit for the patient can be identified based at least in part on the evaluation of the schedule.
Under current practice, 67 participants will be stimulated with HP-hMG, following the same pattern described for the group of recombinant FSH. In this case, the initial dose is 225-300 IU / day of HP-hMG (Menopur®). From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of HP-hMG according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) is given if there is no risk of OHSS and 36 hours then held the follicular puncture for oocyte retrieval .
Browning of white adipose tissue is hallmarked by increased mitochondrial density and metabolic improvements. However, it remains largely unknown how mitochondrial turnover and quality control are regulated during adipose browning. In the present study, we found that mice lacking adipocyte FoxO1, a transcription factor that regulates autophagy, adopted an alternate mechanism of mitophagy to maintain mitochondrial turnover and quality control during adipose browning. Post-developmental deletion of adipocyte FoxO1 (adO1KO) suppressed Bnip3 but activated Fundc1/Drp1/OPA1 cascade, concurrent with up-regulation of Atg7 and CTSL. In addition, mitochondrial biogenesis was stimulated via the Pgc1α/Tfam pathway in adO1KO mice. These changes were associated with enhanced mitochondrial homeostasis and metabolic health (e.g., improved glucose tolerance and insulin sensitivity). By contrast, silencing Fundc1 or Pgc1α reversed the changes induced by silencing FoxO1, which impaired mitochondrial quality control and function. Ablation of Atg7 suppressed mitochondrial turnover and function, causing metabolic disorder (e.g., impaired glucose tolerance and insulin sensitivity), regardless of elevated markers of adipose browning. Consistently, suppression of autophagy via CTSL by high-fat diet was associated with a reversal of adO1KO-induced benefits. Our data reveal a unique role of FoxO1 in coordinating mitophagy receptors (Bnip3 and Fundc1) for a fine-tuned mitochondrial turnover and quality control, underscoring autophagic clearance of mitochondria as a prerequisite for healthy browning of adipose tissue.
After the initial baseline evaluation, the delayed cognitive fitness training group participants will receive only standard of care for 10 weeks ("no intervention" period). Starting in week 11, participants in this arm will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants will go for another 10 weeks with only standard of care treatment.
Participants in this group will take only calcium and vitamin D supplements. Biopsies will be performed at Week 7. Participants will then be offered the standard care for osteoporosis or they may enter the study in Group 4 or 5.
Participants of the first group will receive the lowest dose level. Participants of each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of STI-6129 is found.